Animate Biosciences applies generative AI to regenerative biology, using multi‑omic data from natural super‑regenerators to design novel peptide therapeutics that target pathological tissue remodeling. Their platform accelerates peptide discovery with high precision, aiming to treat conditions across organs—such as pulmonary, cardiac, dermatologic, and hepatic diseases—where current therapies are limited or only palliative. By focusing on peptide‑based regeneration, they seek to improve both lifespan and healthspan.
Funding
Funding not disclosed
Founders
Product
Problem
Pathological tissue remodeling causes progressive damage to organs such as the lung, skin, heart, and liver, contributing to nearly half of global deaths. Existing therapies are largely palliative, organ‑specific, and do not restore lost tissue function, leaving many patients without effective treatment options.
Solution
Animate Biosciences applies a proprietary AI platform that integrates multi‑omic data from naturally occurring super‑regenerators to design novel therapeutic peptides. The system rapidly generates peptide sequences predicted to reverse or prevent maladaptive tissue remodeling across multiple organ systems. These peptides are engineered to rebuild damaged tissue with high fidelity, aiming to restore function rather than merely alleviate symptoms. By targeting the underlying remodeling processes, the approach seeks to extend both lifespan and healthspan for diseases lacking disease‑modifying treatments. The platform enables a pipeline from computational design through preclinical validation toward scalable manufacturing of peptide therapeutics.
Target Audience
Primary customers are pharmaceutical and biotech companies developing disease‑modifying therapies for organ failure, as well as research institutions focused on regenerative medicine and tissue engineering.
Features
- AI‑driven generative design that leverages multi‑omic datasets from regenerative species to predict high‑affinity, bioactive peptide candidates
- Rapid in‑silico screening and optimization pipeline that reduces lead identification time from years to months
- Peptide therapeutics engineered for tissue‑specific targeting and regenerative signaling pathways
- Preclinical development program covering pulmonary, dermatological, cardiac, and hepatic indications
- Scalable peptide synthesis and formulation processes compatible with standard manufacturing infrastructure